Angiopoietin-1 in the treatment of ischemia and sepsis

Nathan M. Novotny, Tim Lahm, Troy A. Markel, Paul R. Crisostomo, Meijing Wang, Yue Wang, Jiangning Tan, Daniel R. Meidrum

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Angiogenic factors have been the focus of a great deal of research for the treatment of ischemic diseases. Described just more than 10 years ago, angiopoietin 1 (Ang-1) has shown promising results in l/R models. Angiopoietin 1 is essential for both embryonic vasculogenesis and adult angiogenesis. Because of its role in maturation of vessels, it seems well suited to complement the angiogenic factor vascular endothelial growth factor (VEGF), which has been shown to induce vascular budding but in isolation produces nonfunctional vessels. This review will focus on (1) Ang-1 and its receptor, Tie-2, and the resultant intracellular signaling cascade; (2) the complex relationship of Ang-1 and VEGF; (3) the results of Ang-1 in l/R and sepsis models; (4) the results of combination (Ang-1 and VEGF) therapies in l/R and sepsis models; and (5) delivery mechanisms for angiogenic factors to ischemic heart.

Original languageEnglish
Pages (from-to)335-341
Number of pages7
JournalShock
Volume31
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Angiopoietin-1
Sepsis
Ischemia
Angiogenesis Inducing Agents
Vascular Endothelial Growth Factor A
Blood Vessels
Research

Keywords

  • Angiopoietin 1
  • Ischemia
  • Sepsis
  • Vascular endothelial growth factor
  • VEGF

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine

Cite this

Novotny, N. M., Lahm, T., Markel, T. A., Crisostomo, P. R., Wang, M., Wang, Y., ... Meidrum, D. R. (2009). Angiopoietin-1 in the treatment of ischemia and sepsis. Shock, 31(4), 335-341. https://doi.org/10.1097/SHK.0b013e3181862c63

Angiopoietin-1 in the treatment of ischemia and sepsis. / Novotny, Nathan M.; Lahm, Tim; Markel, Troy A.; Crisostomo, Paul R.; Wang, Meijing; Wang, Yue; Tan, Jiangning; Meidrum, Daniel R.

In: Shock, Vol. 31, No. 4, 04.2009, p. 335-341.

Research output: Contribution to journalArticle

Novotny, NM, Lahm, T, Markel, TA, Crisostomo, PR, Wang, M, Wang, Y, Tan, J & Meidrum, DR 2009, 'Angiopoietin-1 in the treatment of ischemia and sepsis', Shock, vol. 31, no. 4, pp. 335-341. https://doi.org/10.1097/SHK.0b013e3181862c63
Novotny, Nathan M. ; Lahm, Tim ; Markel, Troy A. ; Crisostomo, Paul R. ; Wang, Meijing ; Wang, Yue ; Tan, Jiangning ; Meidrum, Daniel R. / Angiopoietin-1 in the treatment of ischemia and sepsis. In: Shock. 2009 ; Vol. 31, No. 4. pp. 335-341.
@article{a9bfed5fca15473fbaf39bd851643399,
title = "Angiopoietin-1 in the treatment of ischemia and sepsis",
abstract = "Angiogenic factors have been the focus of a great deal of research for the treatment of ischemic diseases. Described just more than 10 years ago, angiopoietin 1 (Ang-1) has shown promising results in l/R models. Angiopoietin 1 is essential for both embryonic vasculogenesis and adult angiogenesis. Because of its role in maturation of vessels, it seems well suited to complement the angiogenic factor vascular endothelial growth factor (VEGF), which has been shown to induce vascular budding but in isolation produces nonfunctional vessels. This review will focus on (1) Ang-1 and its receptor, Tie-2, and the resultant intracellular signaling cascade; (2) the complex relationship of Ang-1 and VEGF; (3) the results of Ang-1 in l/R and sepsis models; (4) the results of combination (Ang-1 and VEGF) therapies in l/R and sepsis models; and (5) delivery mechanisms for angiogenic factors to ischemic heart.",
keywords = "Angiopoietin 1, Ischemia, Sepsis, Vascular endothelial growth factor, VEGF",
author = "Novotny, {Nathan M.} and Tim Lahm and Markel, {Troy A.} and Crisostomo, {Paul R.} and Meijing Wang and Yue Wang and Jiangning Tan and Meidrum, {Daniel R.}",
year = "2009",
month = "4",
doi = "10.1097/SHK.0b013e3181862c63",
language = "English",
volume = "31",
pages = "335--341",
journal = "Shock",
issn = "1073-2322",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Angiopoietin-1 in the treatment of ischemia and sepsis

AU - Novotny, Nathan M.

AU - Lahm, Tim

AU - Markel, Troy A.

AU - Crisostomo, Paul R.

AU - Wang, Meijing

AU - Wang, Yue

AU - Tan, Jiangning

AU - Meidrum, Daniel R.

PY - 2009/4

Y1 - 2009/4

N2 - Angiogenic factors have been the focus of a great deal of research for the treatment of ischemic diseases. Described just more than 10 years ago, angiopoietin 1 (Ang-1) has shown promising results in l/R models. Angiopoietin 1 is essential for both embryonic vasculogenesis and adult angiogenesis. Because of its role in maturation of vessels, it seems well suited to complement the angiogenic factor vascular endothelial growth factor (VEGF), which has been shown to induce vascular budding but in isolation produces nonfunctional vessels. This review will focus on (1) Ang-1 and its receptor, Tie-2, and the resultant intracellular signaling cascade; (2) the complex relationship of Ang-1 and VEGF; (3) the results of Ang-1 in l/R and sepsis models; (4) the results of combination (Ang-1 and VEGF) therapies in l/R and sepsis models; and (5) delivery mechanisms for angiogenic factors to ischemic heart.

AB - Angiogenic factors have been the focus of a great deal of research for the treatment of ischemic diseases. Described just more than 10 years ago, angiopoietin 1 (Ang-1) has shown promising results in l/R models. Angiopoietin 1 is essential for both embryonic vasculogenesis and adult angiogenesis. Because of its role in maturation of vessels, it seems well suited to complement the angiogenic factor vascular endothelial growth factor (VEGF), which has been shown to induce vascular budding but in isolation produces nonfunctional vessels. This review will focus on (1) Ang-1 and its receptor, Tie-2, and the resultant intracellular signaling cascade; (2) the complex relationship of Ang-1 and VEGF; (3) the results of Ang-1 in l/R and sepsis models; (4) the results of combination (Ang-1 and VEGF) therapies in l/R and sepsis models; and (5) delivery mechanisms for angiogenic factors to ischemic heart.

KW - Angiopoietin 1

KW - Ischemia

KW - Sepsis

KW - Vascular endothelial growth factor

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=64849114225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64849114225&partnerID=8YFLogxK

U2 - 10.1097/SHK.0b013e3181862c63

DO - 10.1097/SHK.0b013e3181862c63

M3 - Article

C2 - 18791498

AN - SCOPUS:64849114225

VL - 31

SP - 335

EP - 341

JO - Shock

JF - Shock

SN - 1073-2322

IS - 4

ER -